VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 365 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $760,000 | -2.3% | 30,955 | -19.9% | 0.44% | -6.0% |
| Q2 2016 | $778,000 | -24.3% | 38,630 | -1.2% | 0.46% | -24.9% |
| Q1 2016 | $1,028,000 | -71.3% | 39,100 | +11.1% | 0.62% | -71.3% |
| Q4 2015 | $3,577,000 | -41.2% | 35,185 | +3.2% | 2.16% | -41.9% |
| Q3 2015 | $6,082,000 | -21.7% | 34,095 | -2.5% | 3.71% | -17.4% |
| Q2 2015 | $7,771,000 | -0.6% | 34,980 | -11.1% | 4.49% | -0.8% |
| Q1 2015 | $7,814,000 | +34.8% | 39,340 | -2.9% | 4.53% | +34.5% |
| Q4 2014 | $5,798,000 | +7.3% | 40,515 | -1.7% | 3.37% | +1.3% |
| Q3 2014 | $5,406,000 | +4.3% | 41,205 | +0.2% | 3.32% | +4.6% |
| Q2 2014 | $5,184,000 | -5.0% | 41,105 | -0.7% | 3.18% | -7.5% |
| Q1 2014 | $5,454,000 | +7.8% | 41,375 | -4.0% | 3.44% | +10.3% |
| Q4 2013 | $5,060,000 | +12.4% | 43,100 | -0.1% | 3.12% | +3.2% |
| Q3 2013 | $4,502,000 | +21.0% | 43,150 | -0.2% | 3.02% | +15.5% |
| Q2 2013 | $3,721,000 | – | 43,225 | – | 2.62% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |